Castillo-de Lira HH, Venegas-Ocampo PJ, Robles-Scott MA, Gutiérrez-Ochoa J, Landa-Soler M, Xochipiltécatl-Muñoz JD

Language: Spanish
References: 12
Page: 6-10
PDF size: 240.05 Kb.

ABSTRACT

Objective: To evaluate cryotherapy as a safe and valid treatment alternative equivalent to radical prostatectomy in localized prostate cancer management.
Materials and methods: A clinical retrospective study was carried out in which 60 case records from the years 2006-2009 of patients diagnosed with localized prostate cancer who underwent cryotherapy (30 patients) or radical prostatectomy (30 patients) were reviewed. The following variables were analyzed: age, Gleason grade, clinical stage, prostate volume, prostate specific antigen (PSA) levels, surgery duration, bleeding, hospital stay and complications.
Results: In the cryotherapy group, surgery duration was a mean 3.5 hours, bleeding was between 30-100 mL with a mean 51 mL and hospital stay was a mean 4.13 days. In the radical prostatectomy group, surgery duration was 3.90 hours, bleeding was from 800-12,500 mL with a mean 2680 mL and hospital stay was a mean 5.07 days. Complications presented in 100% of patients that underwent cryotherapy, the most frequent of which was perineal ecchymosis. In the radical prostatectomy group complications presented in 30% of patients.
Conclusions: The advantages of cryotherapy over radical prostatectomy are reduced blood loss and less serious complications during and after the procedure. Adequate patient selection is necessary for both procedures in order to choose the most appropriate and effective treatment and consequently obtain better results for each patient.

REFERENCES

1. Thomas A. Stamey, John E Mc-Neal. Adenocarcinoma of the prostate. Elsevier. Philadelphia, PA, EUA. Campbell´s Urology 7th Edition. 2007;(Cap. 29):1159-1221.

2. Eggener SE, Scardino PT, Carroll PR. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol 2007;178(6):2260-7

3. Richie JP, D´Amico AV. Prostate Cancer. Urologic oncology. Elsevier Saunders. 8th Edition 2005;(Cap. 26):465-477.

4. Johansen TE. Crioterapia prostática como tratamiento primario en pacientes con cáncer de próstata. Actas Urol Esp 2007;31(6):651-9.

5. Speight JL, Roach M. New techniques and management options for localized prostate cancer. Rev Urol 2006;8(Suppl 2):S22-9.

6. Hubosky SG, Fabrizio MD. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life. J Endourol 2007;21(12):1521-31.

7. Pontones Moreno JL, Morera Martínez JF, Vera Donoso CD. Criocirugía en el tratamiento del cáncer de próstata. Actas Urol Esp 2007;31(3):211-32.

8. Theodorescu D. Cancer cryotherapy: evolution and biology. Rev Urol 2004;6(Suppl 4):S9-19.

9. Pisters LL, Rewcastle JC, Donnelly BJ, Lugnani FM, Katz AE, Jones JS. Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol 2008;180(2):559-63.

10. Aus G, Abbou CC, Bolla M, Heidenreich A. Guidelines on prostate cancer, European Association of Urology, Guidelines Milán, Italia. 2007

11. Richie JP, D´Amico AV. Cryotherapy of Prostate Cancer. Elsevier. Philadelphia, PA. EUA. Campbell´s Urology. 9th Edition 2007;(Cap. 101):3032-52.

12. Jones JS, Rewcastle JC, Donnelly BJ. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol 2008;180(2):554-8.